ClinicalTrials.gg
RecruitingNCT07339488ILDR-03Updated Oct 5, 2026

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of Intestinal Low Dose Radiotherapy-1Gy and PD-1/PD-L1 inhibitors in Borderline Resectable Carcinoma, Unresectable Cancer and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chuangzhen Chen. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Chuangzhen Chen · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 5, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China — 175 open to participants now, 214 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
267th of 352
39 · median 70
Started
2025
with 30 others
Phase 2
213 of 402
97 open now
Primary completion
2029-10
later than 204 of 213 live
Registered
346th of 402
by date

Among the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 267th largest by planned enrollment of the 352 interventional ones that give a count, is one of 31 that started in 2025, is one of 213 in phase 2, reaches primary completion later than 204 of the 213 other live ones, and was the 346th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

175 of the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

170 more — sign in →

All 175 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality. Cases of EC in China account for over 50% of the global total, with squamous cell carcinoma being the primary pathological type. Locally advanced EC (LAEC), particularly cases where radical surgical resection is not feasible, exhibits high recurrence rates and low 5-year survival rates. However, studies have shown that patients with LAEC who undergo comprehensive treatment followed by surgery experience significantly prolonged survival and improved quality of life compared to those who do not receive surgical intervention.

Current conversion treatment regimens under investigation include: chemotherapy alone, chemoradiotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with chemoradiotherapy-each of these approaches has distinct advantages and limitations. Immunochemotherapy has emerged as a current research focus: it not only demonstrates significantly superior efficacy compared to chemotherapy alone but also exhibits lower cumulative toxicity than radiotherapy-combined conversion regimens, resulting in a more favorable overall benefit-risk ratio. As such, it represents the most promising conversion treatment strategy.

Retrospective and prospective clinical studies have shown that low-dose radiotherapy targeting the small intestine can enhance the anti-tumor response of immune checkpoint inhibitors (ICIs) in patients with advanced solid tumor, prolong their overall survival, and increase the incidence of the abscopal effect. Further mechanistic investigations have revealed that intestinal low-dose radiotherapy (ILDR) may augment the immune cancerous lethality by modulating the gut microbiota and their metabolic profiles.

Based on the findings from these preliminary studies, the current research plans to conduct a prospective phase II single-arm clinical trial to investigate the efficacy and safety of ILDR combined with immunochemotherapy as conversion therapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma (BR/UR ESCC). This research plans to enroll at least 39 evaluable cases or a total of 39 cases in two seperated stages, focusing on patients with thoracic BR/UR ESCC. Patients will receive a single fraction of ILDR with a mean dose of 1 Gy, concurrently with 3 cycles of albumin-bound paclitaxel (260 mg/m² on day 1), cisplatin (75 mg/m² on day 1), and tislelizumab (200 mg on day 1). The efficacy and safety of the treatment will be evaluated throughout the study.

03

Conditions studied

  • Borderline Resectable Carcinoma
  • Unresectable Cancer
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Immune Checkpoint Inhibitor
  • Chemotherapy
  • Radiotherapy
  • Tislelizumab
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients voluntarily enroll in this study, sign an form, and demonstrate good compliance.
  2. Age ≥18 years and ≤75 years; both sexes are eligible.
  3. performance status score of 0-1.
  4. confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.
  5. Thoracic esophageal cancer.
  6. Unresectable lesions, defined as: T4 stage; Borderline resectable T3 disease, in which imaging cannot exclude invasion of adjacent organs or structures, such as the trachea, bronchi, or aorta; T3 disease with supraclavicular lymph node ; or clinically confirmed unresectable disease by the surgeon.
  7. No prior history of anti-tumor treatment, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.
  8. Baseline laboratory requirements (within 7 days prior to enrollment):

    Hematology:

    1. ≥90 g/L (no transfusion within 14 days)
    2. NEUT ≥1.5×10⁹/L
    3. ≥100×10⁹/L
    4. WBC≥3×10⁹/L

    Biochemistry:

    1. and AST≤2.5×
    2. ≤1.5×ULN
    3. SCr≤1.5×ULN; or ≥60 mL/min Coagulation: , INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3/FT4 levels should also be considered; eligible if FT3/FT4 are normal) Echocardiography: ≥50%
  9. Female subjects need to agree to use during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.
  10. No psychological, familial, social, or geographical factors that may impair protocol adherence.
  11. Other parameters meet general clinical trial enrollment criteria.
  12. The subject or authorized representative has read, fully understands the patient information sheet, and signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with distant other than supraclavicular lymph node metastases.
  2. Presence or high risk of esophageal perforation.
  3. Patients with to radiotherapy or (ICI) therapy.
  4. Subjects with active, uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.
  5. Respiratory depression, airway obstruction, or tissue hypoxia.
  6. Severe cardiac disease (i.e., functional class II or higher).
  7. Markedly abnormal liver or kidney function (i.e., indicators >3 times the ).
  8. Active , , , or syphilis.
  9. Active brain disease or central nervous system/meningeal metastases with significant symptoms, or impaired decision-making capacity.
  10. to drugs included in the trial.
  11. Drug and/or alcohol abuse.
  12. Pregnant or lactating women.
  13. Concurrent participation in another therapeutic clinical trial.
  14. Major surgical procedure within 30 days prior to enrollment.
  15. Use of antibiotics, antifungals, antivirals, or antiparasitics within 4 weeks prior to registration.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    ILDR plus immunochemotherapy plus surgery

    1Gy/1F ILDR + albumin-bound paclitaxel (3 cycles of 260 mg/m² on day 1), cisplatin (3 cycles of 75 mg/m² on day 1), and tislelizumab (3 cycles of 200 mg on day 1) + surgery

    Radiation: Intestinal Low Dose Radiotherapy-1Gy · Drug: PD-1/PD-L1 inhibitors · Drug: Chemotherapy · Procedure: Surgery

Interventions

  • RadiationIntestinal Low Dose Radiotherapy-1Gy

    1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.

  • DrugPD-1/PD-L1 inhibitors

    Drug page: Immune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3 cycles of tislelizumab(200 mg D1 q3w)

  • DrugChemotherapy

    3 cycles of albumin-bound paclitaxel(260 mg/m2 D1 q3w)+ cisplatin(75 mg/m2 D1 q3w)

  • ProcedureSurgery

    McKeown esophagectomy or laparoscopic-assisted McKeown esophagectomy is recommended, with either two-and-a-half-field lymphadenectomy or three-field lymph node dissection.

06

What researchers measure

Primary outcomes

  1. 1-Year Progression-Free Survival Rate (1y-PFSR)

    The 1y-PFSR is defined as the proportion of patients who remain alive without documented cancer progression 1 year after the initiation of treatment.

    Time frame: Up to 12 months after the initiation of treatment.

Secondary outcomes

  1. Pathological Complete Response (pCR) Rate

    The proportion of patients who, following conversion therapy, exhibit no residual invasive cancer cells in either the primary tumor site or regional lymph nodes upon pathological evaluation of surgical resection specimens, expressed as a percentage of the total treated population.

    Time frame: From postoperative day 0 up to 15 weeks postoperatively.

  2. Objective Response Rate (ORR)

    Proportion of patients achieving complete response (CR) or partial response (PR) (sustained ≥4 weeks) per RECIST v1.1 and iRECIST criteria.

    Time frame: Baseline, every 6 weeks during conversion therapy, postoperation, every 4 months following the first postoperative assessment with a maximum duration of 12 months.

  3. Major Pathological Response (MPR) Rate

    MPR is defined as the proportion of patients with ≤10% residual viable tumor cells in surgical specimens following treatment. Pathological evaluation requires standardized sampling and separate assessment of lymph node metastases.

    Time frame: From postoperative day 0 up to 15 weeks postoperatively.

  4. Disease Control Rate (DCR)

    DCR is defined as the proportion of patients achieving complete response (CR), partial response (PR), or stable disease (SD) post-treatment, as measured by RECIST 1.1 and iRECIST criteria.

    Time frame: Baseline, every 6 weeks during conversion therapy, postoperation, every 4 months following the first postoperative assessment with a maximum duration of 12 months.

  5. Adverse Event Incidence Rate

    The proportion of patients experiencing adverse events of any grade (graded according to CTCAE 6.0, Common Terminology Criteria for Adverse Events, grades 1-5) during treatment.

    Time frame: Up to 12 months after surgery.

  6. 1-Year Overall Survival Rate (1y-OSR)

    The 1y-OSR is defined as the proportion of patients who have not experienced all-cause death at 12 months following the initiation of treatment.

    Time frame: Up to 12 months after the initiation of treatment.

  7. Surgical Conversion Rate

    Defined as the proportion of initially unresectable patients who are converted to resectable status following treatment.

    Time frame: Up to 12 months after surgery.

  8. R0 Resection Rate

    Defined as the proportion of radical surgeries achieving microscopically negative margins (margin ≥1 mm).

    Time frame: From postoperative day 0 up to 15 weeks postoperatively.

Other outcomes

  1. Peripheral Blood Immune Landscape

    Flow cytometry analysis is performed on peripheral blood samples.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

  2. Peripheral Blood Transcriptomics

    RNA sequencing is performed on peripheral blood samples.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

  3. Peripheral Blood Immune Receptor Repertoire

    TCR sequencing is performed on peripheral blood samples.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

  4. Serum Metabolomics

    The wide arrays of metabolites in peripheral blood samples are analyzed qualitatively and quantitatively.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

  5. Serum Cytokine Analysis

    The wide arrays of cytokines in peripheral blood samples are analyzed qualitatively and quantitatively.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

  6. Tissue Transcriptomics

    RNA sequencing is performed on tissue samples.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

  7. Tissue Immune Receptor Repertoire

    TCR sequencing is performed on tissue samples.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

  8. Tissue Immunohistochemistry

    Multi-marker fluorescent immunohistochemistry is performed on tissue samples.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

  9. Changes of Intestinal Flora

    Fecal samples are analyzed by metagenomics sequencing.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

  10. Fecal Metabolomics

    The wide arrays of metabolites in fecal samples are analyzed qualitatively and quantitatively.

    Time frame: Baseline, and at a follow-up time point within 6 weeks after completion of conversion therapy but before surgical resection.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2029, 46 months after the start.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 46 months is above that.

Counting every sponsor, half of 174 studies reached it within 41 months; a quarter within 28 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Nov 2028 → Oct 2029 and completion Nov 2028 → Oct 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Jan 14, 2026
StartActual
Dec 5, 2025
Primary completionEst.
Oct 30, 2029was Nov 2028
CompletionEst.
Oct 30, 2029was Nov 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2028→Oct 30, 2029
Oct 5, 2026
Study completion
Nov 1, 2028→Oct 30, 2029
Oct 5, 2026
Enrollment
43→39
Oct 5, 2026
Eligibility
1 inclusion criterion edited; 3 exclusion criteria removed
What changed in the criteria
Inclusion criteria
  • EditedUnresectable lesions, defined as: T4 stage; marginallyBorderline resectable T3 stage (invading otherdisease, in which imaging cannot exclude invasion of adjacent organs or structures, e.g.,such as the trachea, bronchusbronchi, or aorta not ruled out by imaging); presence or absence of unresectable lymph nodes or metastatic lymph nodes invading adjacent organs; presence or absence ofT3 disease with supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon.
Exclusion criteria
  • RemovedPatients who previously experienced unacceptable toxicity after receiving ICI therapy.
  • RemovedPatients with a history of thoracoabdominal/pelvic radiotherapy within 6 months prior to enrollment.
  • RemovedAdverse reactions from prior anti-tumor treatment have not recovered to CTCAE v5.0 grade≤1 (excluding toxicities deemed by the investigator to pose no safety risk, such as fatigue or alopecia).
Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Pathological Complete Response (pCR) RateNow 1-Year Progression-Free Survival Rate (1y-PFSR)Time frame: From postoperative day 0 up to 15 weeks postoperatively. → Up to 12 months after the initiation of treatment.
Oct 5, 2026
Secondary outcomes
1 edited, 1 time frame changed
What changed in the outcomes
  • ChangedBefore 1-Year Disease-Free Survival Rate (1y-DFSR)Now Pathological Complete Response (pCR) RateTime frame: Up to 12 months after surgery. → From postoperative day 0 up to 15 weeks postoperatively.
  • Time frame1-Year Overall Survival Rate (1y-OSR)Up to 12 months after surgery. → Up to 12 months after the initiation of treatment.
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Nov 1, 2028→Oct 30, 2029
    Study completion Nov 1, 2028→Oct 30, 2029
    Enrollment 43→39
    Eligibility 1 inclusion criterion edited; 3 exclusion criteria removed
    What changed in the criteria
    Inclusion criteria
    • EditedUnresectable lesions, defined as: T4 stage; marginallyBorderline resectable T3 stage (invading otherdisease, in which imaging cannot exclude invasion of adjacent organs or structures, e.g.,such as the trachea, bronchusbronchi, or aorta not ruled out by imaging); presence or absence of unresectable lymph nodes or metastatic lymph nodes invading adjacent organs; presence or absence ofT3 disease with supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon.
    Exclusion criteria
    • RemovedPatients who previously experienced unacceptable toxicity after receiving ICI therapy.
    • RemovedPatients with a history of thoracoabdominal/pelvic radiotherapy within 6 months prior to enrollment.
    • RemovedAdverse reactions from prior anti-tumor treatment have not recovered to CTCAE v5.0 grade≤1 (excluding toxicities deemed by the investigator to pose no safety risk, such as fatigue or alopecia).
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Pathological Complete Response (pCR) RateNow 1-Year Progression-Free Survival Rate (1y-PFSR)Time frame: From postoperative day 0 up to 15 weeks postoperatively. → Up to 12 months after the initiation of treatment.
    Secondary outcomes 1 edited, 1 time frame changed
    What changed in the outcomes
    • ChangedBefore 1-Year Disease-Free Survival Rate (1y-DFSR)Now Pathological Complete Response (pCR) RateTime frame: Up to 12 months after surgery. → From postoperative day 0 up to 15 weeks postoperatively.
    • Time frame1-Year Overall Survival Rate (1y-OSR)Up to 12 months after surgery. → Up to 12 months after the initiation of treatment.
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07339488
Lead sponsor
Chuangzhen Chen
Collaborators
BeOne Medicines
Responsible party
Chuangzhen Chen (Director, Shantou University Medical College) — Sponsor-investigator
First posted
Jan 14, 2026
Start date
Dec 5, 2025
Primary completion
Oct 30, 2029 (estimated)
Completion
Oct 30, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Chuangzhen Chen
Contact
czchen2@stu.edu.cn
+86 13923995569

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion